Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureBolun Li, Linyi Liu, En Luo, Hanghang Liu, Clifford J. Rosen
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Assessment of fracture risk in women with eating disorders: the utility of dual-energy x-ray absorptiometry (DXA)-Clinical cohort study
10.1002/eat.23245 · 2020
Assessment of sex differences in fracture risk among patients with Anorexia Nervosa: a population-based cohort study using the health improvement network
2017
Endocrine consequences of anorexia nervosa
10.1016/s2213-8587(13)70180-3 · 2014
Estrogen and the skeleton
10.1016/j.tem.2012.03.008 · 2012
Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism
10.1210/jc.2003-030532 · 2003
Cortisol decreases bone formation by inhibiting periosteal cell proliferation
10.1210/endo-114-2-477 · 1984
Mechanisms of glucocorticoid action in bone
10.1111/j.1749-6632.2002.tb04204.x · 2002
Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa
10.1016/j.bone.2008.03.007 · 2008
Peptide YY regulates bone remodeling in mice: a link between gut and skeletal biology
10.1371/journal.pone.0040038 · 2012
PYY is a negative regulator of bone mass and strength
10.1016/j.bone.2019.07.011 · 2019
Anorexia Nervosa and osteoporosis
10.1007/s00223-021-00826-3 · 2022
Physiologic regulators of bone turnover in young women with anorexia nervosa
10.1067/mpd.2002.125003 · 2002
Dehydroepiandrosterone sulfate, osteoprotegerin and its soluble ligand sRANKL and bone metabolism in girls with anorexia nervosa
10.5604/17322693.1009971 · 2012
The oxytocin-bone axis
10.1111/jne.12120 · 2014
Oxytocin and anorexia nervosa: a review of the emerging literature
10.1002/erv.2252 · 2013
Low PTH levels in adolescents with Anorexia Nervosa
10.3389/fped.2020.00099 · 2020
Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis
10.1007/s00592-025-02468-5 · 2025
Glucagon-like Peptide-1 receptor agonists and diabetic osteopathy: another positive effect of incretines? A 12 months longitudinal study
10.1007/s00223-024-01240-1 · 2024
Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial
10.1001/jamanetworkopen.2024.16775 · 2024
Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial
10.1016/j.eclinm.2024.102624 · 2024
Use of glucagon-like-peptide 1 receptor agonists and risk of fracture as compared to use of other anti-hyperglycemic drugs
10.1007/s00223-015-0037-y · 2015
Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis
10.1007/s00223-015-9993-5 · 2015
Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials
10.1111/1753-0407.12102 · 2014
Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: a meta-analysis of randomized controlled trials
10.1016/j.bone.2024.117338 · 2025
Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials
10.1007/s00198-018-4649-8 · 2018
Effects of anti-diabetic drugs on fracture risk: a systematic review and network meta-analysis
10.3389/fendo.2021.735824 · 2021
Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials
10.1007/s12020-014-0361-4 · 2015
10.1016/j.yexcr.2017.09.018
10.1016/j.yexcr.2017.09.018 · 2017
Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway
10.3389/fphar.2025.1539411 · 2025
The crucial role of beta-catenin in the osteoprotective effect of semaglutide in an ovariectomized rat model of osteoporosis
10.1007/s00210-024-03378-z · 2025
Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes
2024
Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R
10.1016/j.biopha.2020.110523 · 2020
Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes
10.1371/journal.pone.0132744 · 2015
Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through β-Catenin
10.1016/j.stemcr.2016.02.002 · 2016
Does diet-induced weight loss lead to bone loss in overweight or Obese adults? A systematic review and meta-analysis of clinical trials
10.1002/jbmr.2564 · 2015
Effect of exercise modality during weight loss on bone health in older adults with obesity and cardiovascular disease or metabolic syndrome: a randomized controlled trial
10.1002/jbmr.3555 · 2018
Reduced bone mineral density is not associated with significantly reduced bone quality in men and women practicing long-term calorie restriction with adequate nutrition
10.1111/j.1474-9726.2010.00643.x · 2011
Relationships between serum leptin and bone markers during stable weight, weight reduction and weight regain in male and female judoists
10.1530/eje.1.02103 · 2006
Areal and volumetric bone mineral density and geometry at two levels of protein intake during caloric restriction: a randomized, controlled trial
10.1002/jbmr.318 · 2011
Effect of oral and transdermal oestrogen therapy on bone mineral density in functional hypothalamic amenorrhoea: a systematic review and meta-analysis
10.1136/bmjsem-2021-001112 · 2021
Treatment-related changes in total hip bone mineral density are applicable to trials of varied study designs and to drugs with differing mechanisms of action: meta-regression results from the FNIH-ASBMR SABRE study
10.1093/jbmr/zjaf100 · doi-reference
Pre-treatment bone mineral density and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project
10.1093/jbmr/zjae068 · doi-reference
One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study
10.1002/jbmr.3622 · doi-reference
Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment
10.1002/jbmr.3735 · doi-reference
Romosozumab treatment in postmenopausal women with osteoporosis
10.1056/nejmoa1607948 · doi-reference
The effect of zoledronic acid on bone microarchitecture and strength after Denosumab and Teriparatide Administration: DATA-HD study extension
10.1002/jbmr.4737 · doi-reference
One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis
10.1056/nejmoa050336 · doi-reference
Glycerol-driven TNAP activation in thermogenesis and mineralization
10.1038/s41586-026-10396-9 · doi-reference
Bone as an endocrine regulator of lipid and energy metabolism
10.1007/s11154-026-10052-7 · doi-reference
Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update
10.1210/clinem/dgaa048 · doi-reference
Effect of protein supplementation on hip bone mineral density, cortical thickness, and bone strength in older adult participants during a caloric restriction and aerobic exercise weight loss intervention: a randomized controlled trial
10.1007/s00198-026-07845-6 · doi-reference
The effect of intentional weight loss on fracture risk in persons with diabetes: results from the look AHEAD randomized clinical trial
10.1002/jbmr.3214 · doi-reference
Effects of weight-bearing and weight-supporting sports on bone mass in males
10.2478/pjst-2022-0015 · doi-reference
T cell–expressed CD40L potentiates the bone anabolic activity of intermittent PTH treatment
10.1002/jbmr.2394 · doi-reference
PTH regulates osteogenesis and suppresses adipogenesis through Zfp467 in a feed-forward, PTH1R-cyclic AMP-dependent manner
10.7554/elife.83345 · doi-reference
The role of Zfp467 in mediating the pro-osteogenic and anti-adipogenic effects on bone and bone marrow niche
10.1016/j.bone.2020.115832 · doi-reference
Conditional loss of Nmp4 in mesenchymal stem progenitor cells enhances PTH-induced bone formation
10.1002/jbmr.4732 · doi-reference
PTH promotes bone anabolism by stimulating aerobic glycolysis via IGF signaling
10.1002/jbmr.2556 · doi-reference
Lactate enhanced the effect of parathyroid hormone on osteoblast differentiation via GPR81-PKC-Akt signaling
10.1016/j.bbrc.2018.06.069 · doi-reference
Progenitor recruitment and adipogenic lipolysis contribute to the anabolic actions of parathyroid hormone on the skeleton
10.1096/fj.201800948rr · doi-reference
Weight loss induced bone loss: mechanism of action and clinical implications
10.1038/s41413-025-00483-4 · doi-reference
Effects of histone deacetylase inhibitor scriptaid and parathyroid hormone on osteocyte functions and metabolism
10.1074/jbc.ra118.007312 · doi-reference
Lipoprotein receptor–related protein 6 is required for parathyroid hormone–induced Sost suppression
10.1111/nyas.12750 · doi-reference
Remodeling- and modeling-based bone formation with teriparatide versus denosumab: a longitudinal analysis from baseline to 3 months in the AVA study
10.1002/jbmr.3309 · doi-reference
SIKs control osteocyte responses to parathyroid hormone
10.1038/ncomms13176 · doi-reference
The role of IL-17 and TH17 cells in the bone catabolic activity of PTH
10.3389/fimmu.2016.00057 · doi-reference
PTH and the regulation of mesenchymal cells within the bone marrow niche
10.3390/cells13050406 · doi-reference
Molecular-based treatment strategies for osteoporosis: a literature review
10.3390/ijms20102557 · doi-reference
Osteoporosis treatment: recent developments and ongoing challenges
10.1016/s2213-8587(17)30188-2 · doi-reference
Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women
10.1002/jbmr.1841 · doi-reference
Primary hyperparathyroidism
10.5603/ep.a2020.0028 · doi-reference
Parathyroid hormone pulsatility: physiological and clinical aspects
10.1038/boneres.2014.49 · doi-reference
Parathyroid hormone receptor agonists in the management of osteoporosis
10.1038/s41584-025-01287-w · doi-reference
Bone microstructure and metabolism changes under the combined intervention of ketogenic diet with intermittent fasting: an in vivo study of rats
10.1538/expanim.18-0084 · doi-reference
Time-restricted eating differentially affects bone health and visceral adipose tissue in older women during caloric restriction
10.1016/j.cdnut.2025.106574 · doi-reference
Time-restricted eating for 12 weeks does not adversely alter bone turnover in overweight adults
10.3390/nu13041155 · doi-reference
Adipsin promotes bone marrow adiposity by priming mesenchymal stem cells
10.7554/elife.69209 · doi-reference
Short‐term caloric restriction induced bone loss in both axial and appendicular bones by increasing adiponectin
10.1111/nyas.14380 · doi-reference
Diet quality and nutritional adequacy during a 2-year calorie restriction intervention: the Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy 2 trial
10.1016/j.ajcnut.2025.101182 · doi-reference
Caloric restriction exerts site-, sex-, and duration-dependent effects on skeletal structure and bone marrow adiposity
10.1530/joe-25-0391 · doi-reference